Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
GABRB1 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit beta-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABRB1 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit beta-1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of GABRB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GABRA5 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABRA5 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of GABRA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GABRA4 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABRA4 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of GABRA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GABRA3 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABRA3 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of GABRA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GABBR2 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid type B receptor subunit 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABBR2 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid type B receptor subunit 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of GABBR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GABRA1 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABRA1 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of GABRA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GABRA2 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GABRA2 Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit alpha-2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of GABRA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FPR1 Biologics Sequence Review Report 2026: N-formyl peptide receptor 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FPR1 Biologics Sequence Review Report 2026: N-formyl peptide receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FPR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FPR3 Biologics Sequence Review Report 2026: N-formyl peptide receptor 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FPR3 Biologics Sequence Review Report 2026: N-formyl peptide receptor 3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FPR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FSHR Biologics Sequence Review Report 2026: Follicle-stimulating hormone receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FSHR Biologics Sequence Review Report 2026: Follicle-stimulating hormone receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FSHR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FPR2 Biologics Sequence Review Report 2026: N-formyl peptide receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FPR2 Biologics Sequence Review Report 2026: N-formyl peptide receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FPR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EDNRB Biologics Sequence Review Report 2026: Endothelin receptor type B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EDNRB Biologics Sequence Review Report 2026: Endothelin receptor type B Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of EDNRB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →